Quintrio
Home

PHARMACEUTICAL PREPARATIONS

GeoVax Labs, Inc. New

GOVX

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Last trade $1.85
Day change -$0.17 (-8.42%)
Day range $1.75 – $2.08
Volume 146,821
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.1M
Price / earnings
—
Price / book
0.96×
Price / sales
—
EV / sales
—
EV / EBITDA
0.06×

Profitability

Earnings per share
-$33.54
Return on assets
-533.32%
Return on equity
-1,591.45%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.46×
Quick ratio
1.46×
Cash ratio
1.01×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.5M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GOVX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$852.28K$1.64M$864.42K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$852.28K$1.64M$864.42K
Selling, general and administrative$1.35M$1.33M$1.37M$1.45M$1.33M$1.54M$1.69M$1.6M
Research and development$2.82M$3.11M$3.9M$2.99M$5.04M$4.73M$5.35M$7.61M
Total operating expenses$4.17M$4.44M$5.27M$4.44M$6.37M$6.27M$7.04M$9.21M
Operating income-$4.17M-$4.44M-$5.27M-$4.44M-$6.37M-$5.42M-$5.41M-$8.34M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.16M-$4.43M-$5.26M-$4.42M-$6.32M-$5.37M-$5.36M-$8.26M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.16M-$4.43M-$5.26M-$4.42M-$6.32M-$5.37M-$5.36M-$8.26M
Net income attributable to common shareholders-$4.16M-$4.43M-$5.26M-$4.42M-$6.32M-$5.37M-$5.36M-$8.26M
EBITDA-$4.17M-$4.43M-$5.26M-$4.42M-$6.36M-$5.4M-$5.39M-$8.32M
Basic earnings per share-$10.56-$23.28-$62.88-$2.29-$150.68-$209.76-$268.80-$21.89
Diluted earnings per share-$10.56-$23.28-$62.88-$2.29-$150.68-$209.76-$268.80-$21.89

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Investing.com

Is Co-Diagnostics National Security’s Next Diagnostic Pick?

Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.

Benzinga

WHO Africa Chief Warns It's A 'Big Mistake' To Underestimate Ebola Outbreak As Deadly Virus Spreads Beyond Congo

The WHO Africa regional director Mohamed Yakub Janabi warned against underestimating the Ebola outbreak in the Democratic Republic of Congo, which has reported 670 suspected cases and 61 confirmed infections. The Bundibugyo strain has no approved vaccine and has already spread to Uganda. Containment efforts are hampered by population movement, misinformation, and community mistrust. Former CDC Director Robert Redfield warned the outbreak could become a significant pandemic.

Benzinga

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

GeoVax Labs (GOVX) shares surged 16.42% to $2.34 as the company highlighted its MVA vaccine platform's potential to address emerging Ebola and hemorrhagic fever threats, following a WHO emergency declaration. The company announced a $3 million private placement and plans Phase 3 testing of its mpox and smallpox vaccine candidate in Q4 2026. Despite the rally, the stock remains down 91% over the past 12 months.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 11, 20261-for-24reverse split
Jan 12, 20261-for-25reverse split
Jan 31, 20241-for-15reverse split
Sep 25, 20201-for-20reverse split
Jan 24, 20201-for-2,000reverse split
May 2, 20191-for-500reverse split
Apr 28, 20101-for-50reverse split